文献速递头痛与眩晕

阿托吉泮在伴或不伴急性药物过度使用的慢性偏头痛中的疗效:随机双盲3期PROGRESS试验

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial.
PubMed 文献 · Neurology · 2024-06-26

本分析为3期PROGRESS试验的亚组分析,评估阿托吉泮30 mg每日两次或60 mg每日一次在伴或不伴急性药物过度使用的慢性偏头痛成人患者中的疗效。在755例改良意向治疗人群中,500例(66.2%)存在基线急性药物过度使用;阿托吉泮组较安慰剂显著降低月偏头痛天数、月头痛天数及急性药物使用天数,并提高≥50%缓解率,伴或不伴药物过度使用亚组结果相似。

要点

  • 阿托吉泮30 mg每日两次和60 mg每日一次均较安慰剂降低慢性偏头痛患者的月偏头痛天数。
  • 在伴急性药物过度使用患者中,阿托吉泮组达到≥50%月偏头痛天数缓解的比值比较安慰剂更高。
  • 阿托吉泮治疗12周后,符合急性药物过度使用标准的患者比例下降52.1%–61.9%。

核心结论

  • 阿托吉泮对伴或不伴急性药物过度使用的慢性偏头痛患者均有效,表现为月偏头痛天数、月头痛天数及急性药物使用天数减少,符合药物过度使用标准的比例下降,患者报告结局改善。

研究设计与样本

  • 3期、12周、随机、双盲、安慰剂对照PROGRESS试验的亚组分析,纳入慢性偏头痛成人患者(病史≥1年,基线4周内月头痛天数≥15天且月偏头痛天数≥8天)。
  • 参与者按1:1:1随机分配至安慰剂、阿托吉泮30 mg每日两次或阿托吉泮60 mg每日一次,治疗12周,按急性药物过度使用状态分析。
  • 改良意向治疗人群共755例,其中500例(66.2%)符合基线急性药物过度使用标准(安慰剂组169例[68.7%],阿托吉泮30 mg每日两次组161例[63.6%],阿托吉泮60 mg每日一次组170例[66.4%])。

主要发现

  • 在伴急性药物过度使用患者中,阿托吉泮30 mg每日两次组较安慰剂的月偏头痛天数最小二乘均数差(LSMD)为-2.7(95%CI -4.0至-1.4),阿托吉泮60 mg每日一次组为-1.9(95%CI -3.2至-0.6)。
  • 月头痛天数LSMD:阿托吉泮30 mg每日两次组-2.8(95%CI -4.0至-1.5),阿托吉泮60 mg每日一次组-2.1(95%CI -3.3至-0.8)。
  • 月急性药物使用天数LSMD:阿托吉泮30 mg每日两次组-2.8(95%CI -4.1至-1.6),阿托吉泮60 mg每日一次组-2.6(95%CI -3.9至-1.3)。
  • 达到≥50%月偏头痛天数缓解的比值比:阿托吉泮30 mg每日两次组2.5(95%CI 1.5-4.0),阿托吉泮60 mg每日一次组2.3(95%CI 1.4-3.7)。
  • 治疗12周后,阿托吉泮组符合急性药物过度使用标准的患者比例下降52.1%–61.9%;无急性药物过度使用亚组观察到相似结果;阿托吉泮改善患者报告结局指标。

关键数值与推荐

  • 急性药物过度使用标准:曲普坦类/麦角类每月≥10天,单纯镇痛药每月≥15天,或曲普坦类/麦角类/单纯镇痛药联合每月≥10天。
  • 主要疗效指标包括月偏头痛天数、月头痛天数、月急性药物使用天数较基线变化,12周内月偏头痛天数≥50%缓解率及患者报告结局。
  • 本研究提供II级证据表明阿托吉泮减少伴或不伴药物过度使用的成人慢性偏头痛患者的月偏头痛天数、月头痛天数及月急性药物使用天数。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Atogepant is an oral, calcitonin gene-related peptide receptor antagonist approved for the preventive treatment of migraine. We evaluated the efficacy of atogepant for the preventive treatment of chronic migraine (CM) in participants with and without acute medication overuse. METHODS: This subgroup analysis of the phase 3, 12-week, randomized, double-blind, placebo-controlled PROGRESS trial evaluated adults with a ≥1-year history of CM, ≥15 monthly headache days (MHDs), and ≥8 monthly migraine days (MMDs) during the 4-week baseline period. Participants were randomized (1:1:1) to placebo, atogepant 30 mg twice daily (BID), or atogepant 60 mg once daily (QD) for 12 weeks and were analyzed by acute medication overuse status (triptans/ergots for ≥10 days per month, simple analgesics for ≥15 days per month, or combinations of triptans/ergots/simple analgesics for ≥10 days per month). Outcomes included change from baseline in mean MMDs, MHDs, and monthly acute medication use days; ≥50% reduction in mean MMDs across 12 weeks; and patient-reported outcome (PRO) measures. RESULTS: Of 755 participants in the modified intent-to-treat population, 500 (66.2%) met baseline acute medication overuse criteria (placebo, n = 169 [68.7%]; atogepant 30 mg BID, n = 161 [63.6%]; atogepant 60 mg QD, n = 170 [66.4%]). The least squares mean difference (LSMD) (95% CI) from placebo in MMDs was -2.7 (-4.0 to -1.4) with atogepant 30 mg BID and -1.9 (-3.2 to -0.6) with atogepant 60 mg QD. Mean MHDs (LSMD [95% CI] -2.8 [-4.0 to -1.5] and -2.1 [-3.3 to -0.8]) and mean acute medication use days (LSMD [95% CI] -2.8 [-4.1 to -1.6] and -2.6 [-3.9 to -1.3]) were reduced and a higher proportion of participants achieved ≥50% reduction in MMDs (odds ratio [95% CI] 2.5 [1.5-4.0] and 2.3 [1.4-3.7]) with atogepant 30 mg BID and atogepant 60 mg QD. There was a 52.1%-61.9% reduction in the proportion of atogepant-treated participants meeting acute medication overuse criteria over 12 weeks. Atogepant improved PRO measures. Similar results were observed in the subgroup without acute medication overuse. DISCUSSION: Atogepant was effective in participants with CM, with and without acute medication overuse, as evidenced by reductions in mean MMDs, MHDs, and acute medication use days; reductions in the proportion of participants meeting acute medication overuse criteria; and improvements in PROs. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov NCT03855137. Submitted: February 25, 2019; first patient enrolled: March 11, 2019. clinicaltrials.gov/ct2/show/NCT03855137. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that atogepant reduces mean MMDs, MHDs, and monthly acute medication use days in adult patients with or without medication overuse.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Goadsby PJ, Friedman DI, Holle-Lee D, et al. Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial. Neurology. 2024. PMID: 38924724. doi:10.1212/WNL.0000000000209584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。